Erik Allen Imel MD
Lipid Metabolism, Osteoporosis & Bone Metabolism Medicine, Parathyroid, Pediatric Endocrinology
Professor, Medicine and Pediatrics, Indiana University School of Medicine
Join to View Full Profile
550 University BlvdSte 2180Indianapolis, IN 46202
Phone+1 317-944-7718
Fax+1 317-944-1289
Dr. Imel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Indiana University School of MedicineFellowship, Pediatric Endocrinology, 2003 - 2007
University of Rochester Medical CenterResidency, Internal Medicine/Pediatrics, 1999 - 2003
University of Cincinnati College of MedicineClass of 1999
Certifications & Licensure
IN State Medical License 2003 - 2027
NY State Medical License 2003 - 2005
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
American Board of Pediatrics Pediatric Endocrinology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification PathNet, Cerner Corporation, 2013-2017
- CMS Meaningful Use Stage Stage 1 Certification PowerChart, Cerner Healthe, Cerner Patient Portal, HealthSentry and P2 Sentinel, Cerner Corporation, 2013-2017
- CMS Meaningful Use Stage Stage 1 Certification Powerchart and Cerner Healthe, Cerner Corporation, 2013-2017
Clinical Trials
- Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) Start of enrollment: 2014 Jul 02
- Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project. Start of enrollment: 2014 Aug 01
- CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis Start of enrollment: 2019 Dec 18
Publications & Presentations
PubMed
- Can transient neonatal osteosclerosis be differentiated from malignant infantile osteopetrosis?Sarah A Ackah, Boaz Karmazyn, Alden Dewey, Michael J Econs, Gang Peng
Bone Reports. 2025-12-01 - Switching from active vitamin D and phosphate supplementation to burosumab significantly corrects lower limb malalignment in pediatric X-linked hypophosphatemia.Leanne M Ward, Erik A Imel, David Frumberg, Lisa Dilworth, Catherine Siener
Journal of Bone and Mineral Research. 2025-11-29 - Using an electronic frailty index and patient reported outcomes to predict sarcopenia risk.Cody A Altherr, Xiao Luo, Haoran Ding, Ziyue Liu, Stuart J Warden
Scientific Reports. 2025-10-09
Journal Articles
- A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults with X‐Linked Hypophosphatemia: W...Thomas Weber, Mary D Ruppe, Anthony A Portale, Erik A Imel, Thomas O Carpenter, Karl L Insogna, Farzana Perwad, Pisit Pitukcheewanont, Journal of Bone and Mineral Research
Press Mentions
Burosumab Effects Persist Long-Term for Children with Rare Form of RicketsSeptember 16th, 2020
Burosumab Improves Symptom Relief in Genetic RicketsJuly 5th, 2019
Clinical Trial Improves Treatment of Genetic RicketsMay 18th, 2019
Grant Support
- FGF23 In Pediatric Phosphate Physiology And X-Linked Hypophosphatemic Rickets.National Institute Of Arthritis And Musculoskeletal And Skin Diseases2009–2011
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
